2nd Quarter - Report

HOSPIRA, INC. for HOSPIRA INC

Firm
Client
Income
—
Expenses
$240,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

S.1244 - FY14 FDA Appropriations bill relating to sequestered user fees.

LobbyistCovered position, as disclosed
JILL DOWELL —
JULIANA REED —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1244 (113th)

Pharmacy PHA

H.R. 486 - relating to the compounding of drug products House Discussion Draft amending 503A of FFDCA with respect to pharmacy compounding S. 959 Compounding and Pedigree bill

LobbyistCovered position, as disclosed
JILL DOWELL —
JULIANA REED —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 959 (113th), H.R. 486 (113th)

Health Issues HCR

HR. 1919 - Safeguarding America's Pharmaceuticals Act of 2013. P.L. 111-148 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products. S. 957 and S. 959 - The Drug Supply Chain of Security Act. Issues relating to generic drug labeling.

LobbyistCovered position, as disclosed
JILL DOWELL —
JULIANA REED —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1919 (113th), S. 957 (113th), S. 959 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.